CD28


Also found in: Wikipedia.

CD28

a type I transmembrane protein present on most CD4 T cells, many CD8 T cells, and most plasma cells that enhances the transcription and stability of IL-2 messenger RNA.
References in periodicals archive ?
In 2006, the phase 1 clinical study was conducted for a CD28 superagonist antibody TGN1412 in six male human volunteers.
8 On the other hand, CD28 speeds up T-cell activities that are important for antigen-specific immune responses.
Utomilumab could potentially enhance T cell proliferation and activity by augmenting the CD28 costimulatory domain of Yescarta with exogenous 4-1BB signaling.
Results showed they retained binding to CD28, ICOS, and HER2, and enhanced interferon-gamma production, promoted CD4 T cell and CD8 T cell proliferation, and promoted cell lysis (tumor killing), demonstrating in vitro proof of principle for T cell stimulation and proliferation in response to HER2-positive tumor cells.
Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis.
CD28 regulates the translation of Bcl-xL via the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway.
Chemokine receptors, CD28, CD4, and CD8 are well-known co-stimulatory receptors, while cytotoxic T-cell lymphocyte antigen-4 (CTLA-4), programmed-death receptor-1 (PD-1), T-cell immunoglobulin and mucin domain-3 (TIM-3), and leukocyte activation gene-3 (LAG-3) are co-inhibitory receptors.
Abatacept, CLTA-4-IgG1, has been developed to block CD28 and CD80 or CD86 interaction leading to the termination T cell activation.
One of his most important findings was to locate a receptor called CD28 that acts like a gas pedal.
Peripheral blood gene expression of B7 and CD28 family members associated with tumor progression and microscopic lymphovascular invasion in colon cancer patients.
1), CD28, RGMb (repulsive guidance molecule family member b), and CTLA-4 (cyto-toxic T lymphocyte antigen-4) are only some of the players.
Examples under current assessment in clinical trials include: mTOR inhibitors; fully humanised antibody biologies; glucocorticoid receptor antagonists; recombinant humanised antibodies; and CD28 inhibitors.